Health Care & Life Sciences » Pharmaceuticals | Nascent Biotech Inc.

Nascent Biotech Inc. | Balance Sheet

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
113.80
107.60
573.40
129.80
117.00
Other Current Assets
1.20
2.10
-
-
-
Total Current Assets
115.00
109.60
573.40
129.80
117.00
Intangible Assets
172.90
828.00
828.00
770.00
-
Total Assets
287.90
937.60
1,401.30
899.80
117.00
Accounts Payable
-
-
-
151.70
203.40
Other Current Liabilities
1,565.20
3,084.60
2,970.10
14.30
-
Total Current Liabilities
1,565.20
3,084.60
2,970.10
166.00
203.40
Long-Term Debt
-
60.00
-
-
-
Total Liabilities
1,565.20
3,144.60
2,970.10
166.00
203.40
Common Equity (Total)
1,277.20
2,207.00
1,568.80
733.80
86.40
Total Shareholders' Equity
1,277.20
2,207.00
1,568.80
733.80
86.40
Total Equity
1,277.20
2,207.00
1,568.80
733.80
86.40
Liabilities & Shareholders' Equity
287.90
937.60
1,401.30
899.80
117.00

About Nascent Biotech

View Profile
Address
601 21st Street
Vero Beach Florida 32960
United States
Employees -
Website http://www.nascentbiotech.com
Updated 07/08/2019
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of various forms of cancer. It focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded in July 15, 2014 and is headquartered in Vero Beach, FL.